[go: up one dir, main page]

DK3215223T3 - Buprenorphindoseringsskemaer - Google Patents

Buprenorphindoseringsskemaer Download PDF

Info

Publication number
DK3215223T3
DK3215223T3 DK15828368.9T DK15828368T DK3215223T3 DK 3215223 T3 DK3215223 T3 DK 3215223T3 DK 15828368 T DK15828368 T DK 15828368T DK 3215223 T3 DK3215223 T3 DK 3215223T3
Authority
DK
Denmark
Prior art keywords
buprenorphin
dosage schemes
schemes
dosage
buprenorphin dosage
Prior art date
Application number
DK15828368.9T
Other languages
English (en)
Inventor
Azmi Nasser
Celine Marielle Laffont
Christian Arthur Heidbreder
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55221448&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3215223(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Application granted granted Critical
Publication of DK3215223T3 publication Critical patent/DK3215223T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK15828368.9T 2014-11-07 2015-11-06 Buprenorphindoseringsskemaer DK3215223T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462076854P 2014-11-07 2014-11-07
US201562100391P 2015-01-06 2015-01-06
US201562112546P 2015-02-05 2015-02-05
US201562199778P 2015-07-31 2015-07-31
PCT/IB2015/002269 WO2016071767A1 (en) 2014-11-07 2015-11-06 Buprenorphine dosing regimens

Publications (1)

Publication Number Publication Date
DK3215223T3 true DK3215223T3 (da) 2020-08-03

Family

ID=55221448

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15828368.9T DK3215223T3 (da) 2014-11-07 2015-11-06 Buprenorphindoseringsskemaer

Country Status (11)

Country Link
US (6) US11000520B2 (da)
EP (1) EP3215223B1 (da)
AU (1) AU2015341490C1 (da)
CA (2) CA3015557C (da)
DK (1) DK3215223T3 (da)
ES (1) ES2808150T3 (da)
HK (1) HK1243368A1 (da)
IL (1) IL251870A0 (da)
NZ (1) NZ731309A (da)
SG (1) SG11201703632WA (da)
WO (1) WO2016071767A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3215223T3 (da) 2014-11-07 2020-08-03 Indivior Uk Ltd Buprenorphindoseringsskemaer
US10646484B2 (en) * 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2018229551A2 (en) 2017-06-16 2018-12-20 Indivior Uk Limited Methods to treat opioid use disorder
AU2019209416A1 (en) 2018-01-22 2020-07-30 Foresee Pharmaceuticals Co., Ltd. Pharmaceutical composition for sustained release delivery of buprenorphine
AU2019357036B2 (en) * 2018-10-11 2024-11-14 Indivior Uk Limited Buprenorphine to treat respiratory depression
JP2022512230A (ja) * 2018-12-14 2022-02-02 ペア セラピューティクス インコーポレイテッド ブプレノルフィン含有製品の誘導を最適化するためのデジタル治療構成要素
US12406173B2 (en) * 2020-10-30 2025-09-02 Servicenow, Inc. Covariate processing with neural network execution blocks

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB784659A (en) 1954-11-26 1957-10-16 Upjohn Co Therapeutic compositions and aqueous suspensions thereof
US4599354A (en) 1985-03-11 1986-07-08 Morton Shulman Composition and method for producing prolonged pain relief
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US5558880A (en) 1989-12-22 1996-09-24 Janssen Pharmaceutica Inc. Pharmaceutical and other dosage forms
NL9000634A (nl) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
RU2178695C2 (ru) 1993-11-19 2002-01-27 Жансен Фармасетика Н.В. Микрокапсулы, содержащие рисперидон, фармацевтическая композиция и способы их получения
WO1995027481A1 (en) 1994-04-08 1995-10-19 Atrix Laboratories, Inc. Liquid delivery compositions
US5453425A (en) 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
US7833543B2 (en) 1995-06-07 2010-11-16 Durect Corporation High viscosity liquid controlled delivery system and medical or surgical device
US20030211157A1 (en) 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5792477A (en) 1996-05-07 1998-08-11 Alkermes Controlled Therapeutics, Inc. Ii Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent
AU713062B2 (en) 1996-06-17 1999-11-25 Janssen Pharmaceutica N.V. Biconvex rapidly disintegrating dosage forms
US6261583B1 (en) 1998-07-28 2001-07-17 Atrix Laboratories, Inc. Moldable solid delivery system
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
US6194006B1 (en) 1998-12-30 2001-02-27 Alkermes Controlled Therapeutics Inc. Ii Preparation of microparticles having a selected release profile
ES2230154T3 (es) 1999-08-27 2005-05-01 Southern Research Institute Composiciones inyectables de buprenorfina y su utilizacion para reduccion del consumo de heroina y alcohol.
US6461631B1 (en) 1999-11-16 2002-10-08 Atrix Laboratories, Inc. Biodegradable polymer composition
US6264987B1 (en) 2000-05-19 2001-07-24 Alkermes Controlled Therapeutics Inc. Ii Method for preparing microparticles having a selected polymer molecular weight
JP4724354B2 (ja) 2001-02-23 2011-07-13 ジェネンテック， インコーポレイテッド 注射用の崩壊性ポリマー
US20040018238A1 (en) 2001-02-26 2004-01-29 Shukla Atul J Biodegradable vehicles and delivery systems of biolgically active substances
US6558702B2 (en) 2001-04-13 2003-05-06 Alkermes Controlled Therapeutics, Inc. Method of modifying the release profile of sustained release compositions
US20140271788A1 (en) 2013-03-15 2014-09-18 Monosol Rx, Llc Sublingual and buccal film compositions
NZ533435A (en) 2001-11-14 2007-10-26 Alza Corp Injectable depot compositions and uses thereof
US7041320B1 (en) 2002-05-31 2006-05-09 Biotek, Inc. High drug loaded injectable microparticle compositions and methods of treating opioid drug dependence
US7736665B2 (en) 2002-05-31 2010-06-15 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine
WO2004043432A2 (en) 2002-11-06 2004-05-27 Alza Corporation Controlled release depot formulations
US7501113B2 (en) 2003-02-04 2009-03-10 Philip Morris Usa Inc. Aerosol formulations and aerosol delivery of buprenorphine
AU2004219595A1 (en) 2003-03-11 2004-09-23 Qlt Usa Inc. Formulations for cell- schedule dependent anticancer agents
KR20060023140A (ko) 2003-05-30 2006-03-13 알자 코포레이션 이식성 탄성중합체 데포 조성물, 이의 용도 및 이의제조방법
AR044926A1 (es) 2003-06-26 2005-10-12 Control Delivery Sys Inc Sistema de suministro de farmacos gelificante in situ
FI20045223L (fi) 2004-06-15 2005-12-16 Bioretec Oy Monitoiminen biohajoava komposiitti ja kirurginen implantti, joka käsittää mainitun komposiitin
US20050032781A1 (en) 2003-08-06 2005-02-10 Elliot Ehrich Methods for administering active agents to CYP 2D6 sensitive patients
US20050048115A1 (en) 2003-08-27 2005-03-03 Murty Mangena Buprenorphine microspheres
US20050281879A1 (en) 2003-11-14 2005-12-22 Guohua Chen Excipients in drug delivery vehicles
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US8329203B2 (en) 2004-01-12 2012-12-11 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
US8221778B2 (en) 2005-01-12 2012-07-17 The Trustees Of The University Of Pennsylvania Drug-containing implants and methods of use thereof
ES2309766T3 (es) 2004-06-04 2008-12-16 Camurus Ab Formulaciones liquidas de liberacion lenta.
BRPI0516308A2 (pt) 2004-10-04 2010-06-15 Qlt Usa Inc composição fluida, métodos de tratamento de uma doença ou disfunção, métodos de liberação local ou sistêmica de um agente biológico, implantes, método de formação de um implante, kit de agente biológico e usos de uma composição fluida
US8313763B2 (en) 2004-10-04 2012-11-20 Tolmar Therapeutics, Inc. Sustained delivery formulations of rapamycin compounds
PT1824460E (pt) 2004-11-10 2015-01-14 Tolmar Therapeutics Inc Um sistema de administração polimérico estabilizado
EP1838285A2 (en) 2004-12-15 2007-10-03 QLT USA, Inc. Sustained delivery formulations of octreotide compounds
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
US20070117828A1 (en) 2005-11-21 2007-05-24 Schering-Plough Animal Health Corp. Pharmaceutical compositions
US20090239891A1 (en) 2006-03-01 2009-09-24 Shukla Atul J Sustained Release Dosage Forms of Analgesic Medications
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
CA2666341C (en) 2006-10-11 2012-01-03 Qlt Usa, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
PT3660073T (pt) 2007-02-15 2023-08-31 Tolmar International Ltd Poli-(lactídeo-co-glicolídeo) de libertação imediata reduzida
EP2907524A1 (en) 2007-05-25 2015-08-19 RB Pharmaceuticals Limited Sustained delivery formulations of risperidone compounds
WO2009032246A2 (en) 2007-09-03 2009-03-12 Nanotherapeutics, Inc. Particulate compositions for delivery of poorly soluble drugs
US20090181068A1 (en) 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
KR101079513B1 (ko) * 2009-05-13 2011-11-03 삼성전기주식회사 범프 인쇄장치 및 그 제어방법
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US8975270B2 (en) * 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
SI2915525T1 (sl) * 2011-09-19 2022-01-31 Orexo Ab Sublingvalne tablete, odporne proti zlorabi, ki vsebujejo buprenorfin in nalokson
WO2014016428A1 (en) 2012-07-26 2014-01-30 Camurus Ab Opioid formulations
TWI473863B (zh) 2012-12-19 2015-02-21 Nanya Plastics Corp 一種可剝離保護膜及其組成物配方
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
GB201419091D0 (en) 2014-10-27 2014-12-10 Camurus Ab Formulations
DK3215223T3 (da) * 2014-11-07 2020-08-03 Indivior Uk Ltd Buprenorphindoseringsskemaer
BR112017013471A2 (pt) 2014-12-23 2018-02-27 Camurus Ab Pré-formulação, formulação farmacêutica, composição de depósito, métodos para administração de um agente bioativo a um organismo humano ou não humano, para preparação de uma composição cristalina líquida, para tratamento ou profilaxia de um indivíduo animal não humano ou humano, para administração de uma pré-formulação para um sujeito que dela necessita, processo para formação de uma pré- formulação, uso de uma mistura cristalina não líquida de baixa viscosidade, dispositivo de administração pré-preenchido, e, kit.
GB201516554D0 (en) 2015-09-18 2015-11-04 Camurus Ab Controlled-release formulations
WO2018229551A2 (en) 2017-06-16 2018-12-20 Indivior Uk Limited Methods to treat opioid use disorder
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder

Also Published As

Publication number Publication date
HK1243368A1 (zh) 2018-07-13
US20230077787A1 (en) 2023-03-16
NZ731309A (en) 2022-02-25
EP3215223A1 (en) 2017-09-13
US20160128997A1 (en) 2016-05-12
CA3015557C (en) 2019-07-16
SG11201703632WA (en) 2017-06-29
AU2015341490B2 (en) 2020-08-13
CA3015557A1 (en) 2016-05-12
US11839611B2 (en) 2023-12-12
IL251870A0 (en) 2017-06-29
US20170354653A1 (en) 2017-12-14
US20220031692A1 (en) 2022-02-03
ES2808150T3 (es) 2021-02-25
US20250213553A1 (en) 2025-07-03
WO2016071767A1 (en) 2016-05-12
AU2015341490A1 (en) 2017-05-18
CA2965895C (en) 2019-08-06
AU2015341490C1 (en) 2021-03-11
CA2965895A1 (en) 2016-05-12
EP3215223B1 (en) 2020-07-01
US11000520B2 (en) 2021-05-11
US20180243292A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
DK3240801T3 (da) Kombinationstumorimmunterapi
DK3209778T3 (da) Kombination
LT3134402T (lt) 4-amino-imidazochinolino junginiai
DK3310231T3 (da) Doseringsindretning
HUE050732T2 (hu) Új vegyületek
HUE042964T2 (hu) Szubsztituált dihidro-izokinolinon vegyületek
HRP20181479T1 (hr) Tekući farmaceutski sastav
HUE042087T2 (hu) Inhalátor
DK3199161T3 (da) Farmaceutisk præparat
DK3215607T3 (da) Phagterapi
DK3171700T3 (da) Infusionsanlæg
CL2015001019S1 (es) Ampolleta
DK3363428T3 (da) Perfusionsdoseringsform
DK3197890T3 (da) Disubstituerede diaryloxybenzoheterodiazolforbindelser
DK3215223T3 (da) Buprenorphindoseringsskemaer
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
DK3359555T3 (da) Doseringsplaner
EP4205699C0 (en) Inhaler
DK3191466T3 (da) Azetidinyloxyphenylpyrrolidinforbindelser
DK3126791T3 (da) Doseringsanordning
PT3152383T (pt) Barreira
HUE039805T2 (hu) Új szulfonilaminobenzamid vegyületek
DK3140050T3 (da) Dosering med visning
EP3325002C0 (en) COMBINED THERAPEUTIC COMPOSITIONS